Format

Send to

Choose Destination
Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26681. Epub 2017 Jun 14.

Outcome of adolescents and young adults compared to children with Hodgkin lymphoma treated with response-based chemotherapy on pediatric protocols: A Children's Oncology Group report.

Author information

1
Valley Children's Healthcare, Cancer and Blood Disorders Center, Madera, California.
2
Children's Hospital of Wisconsin, Milwaukee, WI.
3
City of Hope and Beckman Research Institute, Duarte, California.
4
University of Rochester Medical Center, Rochester, New York.
5
Department of Pediatrics, West Virginia University, Charleston, West Virginia.
6
University of Illinois College of Medicine at Peoria, Peoria, Illinois.

Abstract

PURPOSE:

We evaluated the outcome of children (<15 years) versus that of adolescents and young adults (AYA; 15-≤ 21 years) treated for Hodgkin lymphoma (HL) in two Pediatric Oncology Group/Children's Oncology Group clinical trials, P9425 and P9426, that used dose-dense, response-based chemotherapy and reduced dose radiotherapy.

PATIENTS AND METHODS:

Subjects 21 years or younger with HL were eligible for these studies. Subjects with low-risk (stages IA, IIA, and IIIA1) without large mediastinal adenopathy biopsy-proven HL, eligible for P9426, were treated with two to four 28-day cycles of doxorubicin, bleomycin, vincristine, and etoposide (ABVE) chemotherapy and 25.5 Gy of involved field radiotherapy. Subjects with intermediate-risk (stages IB, IIA, IIIA1 with large mediastinal adenopathy, and IIIA2) and high-risk (stages IIB, IIIB, and IV) biopsy-proven HL, eligible for P9425, were treated with three to five 21-day cycles of ABVE plus prednisone and cyclophosphamide (ABVE-PC) chemotherapy and 21 Gy of involved region radiotherapy. We compared the 5-year event-free survival (EFS), based on Kaplan-Meier product-limit method, of children versus that of AYA.

RESULTS:

Four hundred seventy-one subjects were enrolled on P9425 and P9426 combined. Of these subjects, 203 were AYA, 104 with intermediate and high-risk HL, and 99 with low-risk HL. The 5-year EFS of children did not significantly differ from that of AYA (85.9 vs. 87.1%) with a median follow up of 7.7 years (P = 0.51).

CONCLUSION:

Given the equivalent and excellent results of therapy, HL represents an opportunity for adult and pediatric cancer treatment collaborative groups to jointly design clinical trials targeted to AYA. These trials should focus on both treatment efficacy and the quality of life of AYA while receiving chemotherapy and in reduction of long-term side effects in the survivorship years.

KEYWORDS:

AYA; Hodgkin lymphoma; pediatric protocols

PMID:
28612375
PMCID:
PMC5799083
DOI:
10.1002/pbc.26681
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center